Currently, rozanolixizumab is administered by the patient’s clinician as a subcutaneous infusion once weekly for six weeks using infusion pump/syringe pumps ... 1 Rozanolixizumab 140 mg/ml solution ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback